Tocilizumab-aazg for Brain Aneurysm
(THRIVE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether the drug tocilizumab-aazg (TYENNE) is safe and can help prevent strokes after a burst brain aneurysm, which is a weakened area in a blood vessel that has leaked blood into the brain. The study administers an infusion of the medication shortly after the aneurysm occurs. Individuals who have experienced a burst brain aneurysm in the last 24 hours and have specific drainage devices in place might be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this potentially groundbreaking treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have been treated with certain medications like IL-6 inhibitors or other specific therapies within a certain timeframe before the trial, you may not be eligible to participate.
Is there any evidence suggesting that tocilizumab-aazg is likely to be safe for humans?
Research has shown that tocilizumab-aazg has been tested for safety in people with burst brain aneurysms. So far, the treatment appears safe and well-tolerated. Previous studies have identified no new safety issues. Tocilizumab-aazg resembles a drug already approved for other uses, which provides some confidence about its safety. However, as this is an early-stage trial, much remains to be learned about its long-term effects. Participants should consider these points when deciding whether to join the trial.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for brain aneurysms, which often involve surgical interventions or endovascular procedures, tocilizumab-aazg offers a novel approach by using an intravenous infusion. This treatment is particularly exciting because it targets inflammation, which is not the primary focus of current standard therapies. By potentially reducing inflammation following a subarachnoid hemorrhage, tocilizumab-aazg could offer an innovative way to mitigate damage and improve recovery outcomes. Researchers are hopeful that this new method could complement existing treatments and offer additional benefits to patients experiencing brain aneurysms.
What evidence suggests that tocilizumab-aazg might be an effective treatment for brain aneurysm?
Research has shown that tocilizumab-aazg, which participants in this trial will receive, might help prevent strokes after a brain aneurysm bursts. Studies indicate that this medication can reduce inflammation and lessen the severity of vasospasms, sudden narrowings of blood vessels. This is important because vasospasms can cause additional brain damage. Although more research is needed, these early findings suggest that tocilizumab-aazg could help protect the brain from further injury after an aneurysm.23467
Who Is on the Research Team?
Brian Hoh, MD
Principal Investigator
University of Florida
Are You a Good Fit for This Trial?
This trial is for patients who've had a burst brain aneurysm, which can lead to subarachnoid hemorrhage and increase the risk of stroke and cognitive issues. Specific eligibility details are not provided, but typically participants must meet certain health standards.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tocilizumab-aazg 6mg/kg IV infusion drip on Day 0 following subarachnoid hemorrhage
Follow-up
Participants are monitored for safety and effectiveness, including adverse events and laboratory measures
What Are the Treatments Tested in This Trial?
Interventions
- Tocilizumab-aazg
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor